Murj has raised $8.5 million in a series B round to help increase marketing and sales efforts for its ICD data-monitoring solution.

Omar Ford

May 9, 2018

2 Min Read
Murj Makes ICD Data More Manageable
GERALT/PIXABAY

Murj, a software solutions company, has developed a cloud-based platform that has the potential to make it easier for hospitals and healthcare facilities to track data coming from implantable cardiac devices (ICDS).

The Santa Cruz, CA-based company has raised $8.5 million in a series B round. The financing will be used to expand  Murj’s salesforce and marketing efforts for the cloud-based platform. The series B round brings Murj’s funding to nearly $14 million since inception, said Todd Butka, the company’s founder and CEO.

Murj’s solution was on display at the Heart Rhythm Society’s annual meeting and received a strong response, Butka said.

“Clinics need to invest in software solutions to expand their ability to manage the implantable cardiac devices,” Butka told MD+DI. “These implantable cardiac devices are increasing in frequency and data coming out and they need a digital workflow.”

Part of the problem with tracking data and keeping up with the workflow is that most of it is done manually. That can be time consuming, Bukta noted.

“Looking through an electronical medical record today against what has happened in the past, when it’s in a PDF – will take you 20 minutes to try and piece something together,” he said. “So, what does Murj do differently? Everything is accessible in just two clicks on our platform. Within a glance and a click, you can literally look at any historical arrhythmia compared to what you’re looking at today.”

As a cloud-based solution, Murj can be activated in as little as 24 hours and requires no software to install or maintain. The solution supports implantable cardiac devices from all major device manufacturers in all care modalities, including in-office interrogations and remote transmissions. The company said the data was secure and well-protected. In the 11 months since the solution launched the company has signed on more than 30 accounts.

Butka noted the company could move into other devices in the cardiovascular market in the future.

 “Heart Failure is a totally separate patient population needing assistance and management,” Butka said. “When you look ahead heart failure is probably next on the horizon.”

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like